Literature DB >> 17490401

Evaluation of T cell immune responses in multi-drug-resistant tuberculosis (MDR-TB) patients to Mycobacterium tuberculosis total lipid antigens.

A S Shahemabadi1, A Zavaran Hosseini, S Shaghsempour, M R Masjedi, M Rayani, M Pouramiri.   

Abstract

Mycobacterium tuberculosis lipid antigens produce significant T cell responses in healthy tuberculin reactor [purified protein derivative (PPD-positive] individuals. In the present study, proliferation and interferon (IFN)-gamma/interleukin (IL)-4 responses were analysed to M. tuberculosis total lipid antigens in T lymphocytes from 25 patients with multi-drug-resistant tuberculosis (MDR-TB). The obtained results were compared with those of 30 asymptomatic healthy PPD-positive and 30 healthy tuberculin skin test negative (PPD-negative) subjects. Peripheral blood mononuclear cells (PBMCs) and T cells (CD4(+) and CD8(+)) were stimulated using autologous immature dendritic cells. Proliferation responses were assessed using 3-{4,5-dimethylthiazol-2-yl}-2,5 diphenyl tetrazolium bromide (MTT). IFN-gamma/IL-4 concentrations in the supernatant of the CD4(+) and CD8(+)T cells were measured by enzyme-linked immunosorbent assay. Proliferation assay showed that the peripheral blood mononuclear cells and CD4(+) T cells from the MDR-TB patients responded significantly less to the M. tuberculosis total lipid antigens than to the CD4(+) T cells in the PPD-positive subjects. Total lipid antigen-specific proliferative responses in the CD8(+) T cells from the MDR-TB patients were minimally detected and the responses were similar to those of the PPD-positive subjects. IFN-gamma production by the CD4(+) T cells stimulated by total lipid antigens from the MDR-TB patients was decreased significantly compared with the PPD-positive individuals, whereas IL-4 production in the patients was elevated. IFN-gamma and IL-4 production in the CD8(+) T cells of the MDR-TB patients was similar to those of the PPD-positive subjects. In conclusion, it is suggested that stimulated CD4(+) T cells by M. tuberculosis total lipid antigens may be shifted to T helper 2 responses in MDR-TB patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17490401      PMCID: PMC1941963          DOI: 10.1111/j.1365-2249.2007.03406.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  T cell activation by lipopeptide antigens.

Authors:  D Branch Moody; David C Young; Tan-Yun Cheng; Jean-Pierre Rosat; Carme Roura-Mir; Peter B O'Connor; Dirk M Zajonc; Andrew Walz; Marvin J Miller; Steven B Levery; Ian A Wilson; Catherine E Costello; Michael B Brenner
Journal:  Science       Date:  2004-01-23       Impact factor: 47.728

2.  Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis.

Authors:  Claudia Manca; Michael B Reed; Sherry Freeman; Barun Mathema; Barry Kreiswirth; Clifton E Barry; Gilla Kaplan
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

3.  Decreased IFN- gamma and increased IL-4 production by human CD8(+) T cells in response to Mycobacterium tuberculosis in tuberculosis patients.

Authors:  S M Smith; M R Klein; A S Malin; J Sillah; K P W J McAdam; H M Dockrell
Journal:  Tuberculosis (Edinb)       Date:  2002       Impact factor: 3.131

Review 4.  Treatment of multidrug-resistant tuberculosis.

Authors:  M D Iseman
Journal:  N Engl J Med       Date:  1993-09-09       Impact factor: 91.245

5.  IL-4 is required for defense against mycobacterial infection.

Authors:  I Sugawara; H Yamada; S Mizuno; Y Iwakura
Journal:  Microbiol Immunol       Date:  2000       Impact factor: 1.955

6.  Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis.

Authors:  Christopher C Dascher; Kenji Hiromatsu; Xiaowei Xiong; Caroline Morehouse; Gerald Watts; Gui Liu; David N McMurray; Kenneth P LeClair; Steven A Porcelli; Michael B Brenner
Journal:  Int Immunol       Date:  2003-08       Impact factor: 4.823

Review 7.  Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis.

Authors:  P J Brennan
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

8.  T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection.

Authors:  Timo Ulrichs; D Branch Moody; Ethan Grant; Stefan H E Kaufmann; Steven A Porcelli
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

9.  Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12 production in macrophages.

Authors:  D N Dao; L Kremer; Y Guérardel; A Molano; W R Jacobs; S A Porcelli; V Briken
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

10.  Characterization of a third form of the human T cell receptor gamma/delta.

Authors:  F Hochstenbach; C Parker; J McLean; V Gieselmann; H Band; I Bank; L Chess; H Spits; J L Strominger; J G Seidman
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

View more
  5 in total

1.  Cellular immune response in MDR-TB patients to different protein expression of MDR and susceptible Mycobacterium tuberculosis: Rv0147, a novel MDR-TB biomarker.

Authors:  Alireza Hadizadeh Tasbiti; Shamsi Yari; Seyed Davar Siadat; Payam Tabarsi; Kayvan Saeedfar; Fatemeh Yari
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

2.  Patients with multidrug-resistant tuberculosis display impaired Th1 responses and enhanced regulatory T-cell levels in response to an outbreak of multidrug-resistant Mycobacterium tuberculosis M and Ra strains.

Authors:  Laura Geffner; Noemí Yokobori; Juan Basile; Pablo Schierloh; Luciana Balboa; María Mercedes Romero; Viviana Ritacco; Marisa Vescovo; Pablo González Montaner; Beatriz Lopez; Lucía Barrera; Mercedes Alemán; Eduardo Abatte; María C Sasiain; Silvia de la Barrera
Journal:  Infect Immun       Date:  2009-08-31       Impact factor: 3.441

3.  The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis.

Authors:  Hong Shen; Rui Min; Qi Tan; Weiping Xie; Hong Wang; Hongqiu Pan; Li Zhang; Hongtao Xu; Xia Zhang; Jianzhong Dai
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

4.  Clinical Efficacy of a Combination of Thymopentin and Antituberculosis Drugs in Treating Drug-Resistant Pulmonary Tuberculosis: Meta Analysis.

Authors:  Yi-Ran Han; Tian-Hao Wang; Wen-Ping Gong; Jian-Qin Liang; Hui-Ru An
Journal:  Ther Clin Risk Manag       Date:  2022-03-25       Impact factor: 2.423

5.  Molecular Epidemiology of Mycobacterium Tuberculosis Strains in the North-West and West of Iran.

Authors:  L Sahebi; K Ansarin; S Hoffner; S Farajnia; M Seyyedi; M Khalili; A Monfaredan
Journal:  Ann Med Health Sci Res       Date:  2015 Sep-Oct
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.